Bioversys Launches Promising Phase 3 Trial for BV100 Drug
BioVersys has initiated a global Phase 3 program for BV100 in ventilator- and hospital-acquired bacterial pneumonia caused by drug-resistant...
No videos found.
Clearmind Medicine Announces 1-for-40 Reverse Share Split
Clearmind Medicine will execute a 1‑for‑40 reverse share split on December 15, 2025, aiming to regain compliance with Nasdaq’s...
VERU Announcing FY2025 Financial Results on December 17th
Veru has set a Q1 2026 start for its Phase 2b Plateau study evaluating enobosarm, a selective androgen receptor...
Telix and Varian Announce Strategic Theranostics Collaboration
Telix Pharmaceuticals has entered a strategic clinical collaboration with Varian, a Siemens Healthineers company, to integrate Telix’s theranostic imaging...
Scilex Holding Closes Warrant Exercise for $20.3M Proceeds
Scilex Holding Company has closed an inducement financing built around existing warrants, securing approximately $20.3 million in gross proceeds....
Amphista Announces New AMX-883 Data, Business Update at ASH
Amphista Therapeutics will present new preclinical data at ASH 2025 for AMX-883, an oral targeted glue degrader of BRD9,...
SciSparc Acquires IP for Multi-Billion-Dollar GERD Market
SciSparc has signed a binding term sheet to acquire the intellectual property portfolio behind Xylo Technologies’ endoscopic systems, including...
Mixie Technologies Signs LOI to Acquire HoloTwin Interest
Mixie Technologies has signed a binding letter of intent to acquire 25% of HoloTwin, with an option to take...
Onco3r’s SIK3 Inhibitor Completes First Phase 1 Cohort
Onco3R Therapeutics has completed the first multiple-ascending-dose cohort and four single-ascending-dose cohorts in a Phase 1 study of O3R-5671,...
RenovoRx CEO to Present at Best Ideas Investment Conference
RenovoRx will present at the iAccess Alpha Best Ideas Winter Investment Conference on December 9, spotlighting early commercial traction...